Vivos Therapeutics (VVOS) AI Stock Analysis

• Market Cap: $17.71M
• Dividend Yield: N/A
• Average Volume (3M): 421.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: 18.76%
• EPS Growth: 60.09%
• Country: US
• Employees: 109
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.49
• Shares Outstanding: 8,988,106
• 10 Day Avg. Volume: 324,525
• 30 Day Avg. Volume: 421,860
• PEG Ratio: 0.02
• Price to Book (P/B): 2.71
• Price to Sales (P/S): 1.43
• P/FCF Ratio: -1.62
• Enterprise Value/Market Cap: 1.98
• Enterprise Value/Revenue: 2.02
• Enterprise Value/Gross Profit: 3.63
• Enterprise Value/Ebitda: -2.19
• 1Y Price Target: $6.25
• Price Target Upside: 217.26% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $2.50 ▲(26.90% Upside)

Vivos Therapeutics' overall score is driven by strong revenue growth and strategic business model shifts, as highlighted in the earnings call. However, financial performance struggles, bearish technical indicators, and poor valuation metrics weigh heavily on the score.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and successful strategic pivots, enhancing long-term business prospects.

Strategic Business Model Shift

Transitioning to a medical practice acquisition model diversifies revenue streams and strengthens competitive positioning in the sleep disorder market.

FDA-Cleared Pediatric Device

FDA clearance for pediatric OSA treatment enhances product credibility and marketability, potentially increasing adoption and revenue.

Negative Factors

High Operational Costs

Rising operational costs can pressure margins and profitability, necessitating efficiency improvements to sustain long-term growth.

Cash Flow Challenges

Ongoing negative cash flow indicates potential liquidity issues, which could hinder investment in growth initiatives and operational stability.

High Leverage

High leverage can strain financial flexibility and increase risk, potentially impacting the company's ability to weather economic downturns.

Vivos Therapeutics Business Overview & Revenue Model

Company Description

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.

How the Company Makes Money

Vivos Therapeutics generates revenue primarily through the sale of its patented medical devices and treatment systems for sleep apnea. The company operates a direct-to-consumer model as well as a business-to-business model, partnering with dental and healthcare professionals to promote and distribute its products. Key revenue streams include the sale of its oral appliances, ongoing treatment subscriptions, and potential licensing agreements. Vivos also benefits from collaborations with healthcare providers and institutions that utilize its technology in patient care, contributing to recurring revenue through follow-up treatments and related services.

Vivos Therapeutics Financial Statement Overview

Summary

Vivos Therapeutics shows positive revenue growth but struggles with profitability and cash flow management. The balance sheet indicates improved equity but high leverage remains a concern.

Income Statement

Vivos Therapeutics has shown some positive revenue growth, with a 8.9% increase in 2024 compared to 2023. However, the company continues to face challenges in achieving profitability, indicated by negative EBIT and EBITDA margins, and a net income of zero in 2024. The consistent negative net profit margin over the years highlights ongoing operational struggles.

Balance Sheet

The balance sheet reflects improving equity, with stockholders' equity rising to $7.95 million in 2024 from $0.41 million in 2023, suggesting strengthened financial stability. However, the debt-to-equity ratio is relatively high, indicating potential leverage risks. The equity ratio remains moderate, demonstrating a balanced asset structure, but further stability is needed.

Cash Flow

The cash flow statement reveals persistent negative free cash flow, with minimal improvement over the years. Operating cash flow remains negative, highlighting ongoing cash burn, although financing activities have supported liquidity. The company needs to focus on improving operational efficiency to enhance cash flow stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.32M	15.03M	13.80M	16.02M	16.89M	13.07M
Gross Profit	9.65M	9.02M	8.27M	10.02M	12.60M	10.41M
EBITDA	-15.97M	-10.55M	-16.68M	-24.36M	-19.54M	-11.24M
Net Income	-17.10M	-11.14M	-13.58M	-23.84M	-20.29M	-12.06M
Balance Sheet
Total Assets	25.64M	15.28M	10.73M	13.72M	33.69M	25.33M
Cash, Cash Equivalents and Short-Term Investments	3.09M	6.26M	1.64M	3.52M	24.03M	18.21M
Total Debt	4.12M	1.51M	2.00M	2.41M	1.63M	1.29M
Total Liabilities	23.11M	7.33M	10.32M	8.92M	8.15M	8.41M
Stockholders Equity	2.53M	7.95M	411.00K	4.80M	25.54M	16.92M
Cash Flow
Free Cash Flow	-14.43M	-13.26M	-12.75M	-20.51M	-18.13M	-5.80M
Operating Cash Flow	-14.39M	-12.69M	-11.95M	-19.59M	-15.73M	-5.68M
Investing Cash Flow	-6.11M	-568.00K	-853.00K	-924.00K	-2.61M	-120.25K
Financing Cash Flow	17.28M	17.88M	10.92M	0.00	24.17M	23.54M

Vivos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.97
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VVOS, the sentiment is Negative. The current price of 1.97 is below the 20-day moving average (MA) of 2.10, below the 50-day MA of 2.42, and below the 200-day MA of 3.23, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 41.22 is Neutral, neither overbought nor oversold. The STOCH value of 21.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VVOS.

Vivos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VVOS	48 Neutral	$17.71M	-1.04	-335.47%	―	18.76%	60.09%
IRIX	46 Neutral	$17.19M	-3.40	-139.29%	―	4.58%	55.26%
ADGM	46 Neutral	$21.82M	-0.21	-210.36%	―	-70.54%	70.03%
CODX	42 Neutral	$16.07M	-0.27	-62.12%	―	-87.84%	29.16%
COCH	41 Neutral	$21.20M	-0.53	―	―	-25.18%	-9.71%

Vivos Therapeutics Corporate Events

Vivos Therapeutics Secures $2M Note with Avondale

On December 5, 2025, Vivos Therapeutics, Inc. entered into a Note Purchase Agreement with Avondale Capital, LLC, resulting in a $2,093,340 promissory note. The company received approximately $1,500,000 in net proceeds, which it intends to use for working capital and general corporate purposes. The note, which is unsecured and non-convertible, includes an original issue discount and requires weekly payments. Vivos Therapeutics has also arranged for its subsidiary to guarantee the company’s obligations under the note. The agreement outlines customary events of default, such as nonpayment and bankruptcy, which could trigger interest accrual or immediate repayment.

Vivos Therapeutics Holds Annual Stockholders Meeting

On November 4, 2025, Vivos Therapeutics, Inc. held its annual meeting of stockholders, where key decisions were made regarding the company’s governance and strategic direction. The stockholders elected six directors to the board for a one-year term, approved an amendment to the 2024 Omnibus Equity Incentive Plan, and ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to impact the company’s operational strategies and financial oversight, reinforcing its governance structure and aligning its incentive plans with future growth objectives.